- High Variability in Levels of Biomarkers in Control Arm of Phase 2b Study May Drive Reassessment of Overall Study Results - - Effects Of PTI-125 on Cognition, Other Analysis and Data Expected 2 nd Half 2020 - - Updated Corporate Presentation Now Available on Website - AUSTIN, Texas , June 03,
- Study Showed High Variability in Levels of CSF Biomarkers Over 28 Days - - Drug Was Safe and Well-tolerated - AUSTIN, Texas , May 15, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today reported top-line results from a Phase 2b study of PTI-125, its lead investigational drug, in
- Anticipates Early Data Readout for Phase 2b Study of PTI-125 in Alzheimer’s Disease - - Approximately $2.9 Million in NIH Research Grants Awarded in 2020 - - Open-Label Study of PTI-125 Initiated in Alzheimer’s Disease - AUSTIN, Texas , May 06, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.
- Grant Will Support an On-going Clinical Evaluation of Lead Investigational Drug PTI-125 in Alzheimer’s Disease - AUSTIN, Texas , April 23, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it
- Top-Line Results of a Phase 2b in Alzheimer’s On Track for Mid-Year 2020 - - Cash Balance Exceeds $26 Million at January 31, 2020 - - $5 Million Net Cash Use Expected in 2020 - AUSTIN, Texas , March 26, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.
Approximately 100 Study Participants Will Receive PTI-125 For 12 Months AUSTIN, Texas , March 25, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the initiation of an open-label extension study to
AUSTIN, Texas , March 19, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced clinical updates and business progress across its pipeline of product candidates under development.
AUSTIN, Texas , Feb. 11, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA ), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that The Journal of Prevention of Alzheimer’s Disease (JPAD), a peer-reviewed journal for the research community,
Top-Line Results Expected Mid-year 2020 AUSTIN, Texas , Jan. 28, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA ), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced it has initiated dosing for the last patient in a Phase 2b study of PTI-125.
